References
- Gupta AK, Gupta G, Jain HC, et al. The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians' offices. J Eur Acad Dermatol Venereol. 2016;30(9):1567–1572.
- Gupta AK, Daigle D, Foley KA. The prevalence of culture-confirmed toenail onychomycosis in at-risk patient populations. J Eur Acad Dermatol Venereol. 2015;29(6):1039–1044.
- Gupta AK, Mays RR, Versteeg SG, et al. Onychomycosis in children: Safety and efficacy of antifungal agents. Pediatr Dermatol. 2018;35(5):552–559.
- Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists’ offices in Ontario, Canada–a multicenter survey of 2001 patients. Int J Dermatol. 1997;36(10):783–787.
- Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43(2):244–248.
- Gupta AK, Chang P, Del Rosso JQ, et al. Onychomycosis in children: prevalence and management. Pediatr Dermatol. 1998;15(6):464–471.
- Solís-Arias MP, García-Romero MT. Onychomycosis in children. A review. Int J Dermatol. 2017;56(2):123–130.
- Feldstein S, Totri C, Friedlander SF. Antifungal therapy for onychomycosis in children. Clin Dermatol. 2015;33(3):333–339.
- Philpot CM, Shuttleworth D. Dermatophyte onychomycosis in children. Clin Exp Dermatol. 1989;14(3):203–205.
- Gupta AK, Sibbald RG, Lynde C, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol. 1997;36(3 Pt 1):395–402.
- Bonifaz A, Saúl A, Mena C, et al. Dermatophyte onychomycosis in children under 2 years of age: experience of 16 cases. J Eur Acad Dermatol Venereol. 2007;21(1):115–117.
- Reichert-Pénétrat S, Contet-Audonneau N, Barbaud A, et al. Epidemiology of dermatophytoses in children living in northeast France: a 5-year study. Pediatr Dermatol. 2002;19(2):103–105.
- Peña-Penabad C, García-Silva J, Almagro M, et al. Superficial white onychomycosis in a 3-year-old human immunodeficiency virus-infected child. J Eur Acad Dermatol Venereol. 2001;15(1):51–53.
- Velthuis PJ, Nijenhuis M. Treatment of onychomycosis with terbinafine in patients with Down's syndrome. Br J Dermatol. 1995;133(1):144–146.
- Rodriguez-Pazos L, Pereiro-Ferreiros M, Pereiro M, et al. Onychomycosis observed in children over a 20-year period. Mycoses. 2011;54(5):450–453.
- Sigurgeirsson B, Kristinsson KG, Jonasson PS. Onychomycosis in Icelandic children. J Eur Acad Dermatol Venereol. 2006;20(7):796–799.
- Gupta AK, Macleod MA, Foley KA, et al. Fungal skin infections. Pediatr Rev. 2017;38(1):8–20.
- Lange M, Roszkiewicz J, Szczerkowska-Dobosz A, et al. Onychomycosis is no longer a rare finding in children. Mycoses. 2006;49(1):55–59.
- Eichenfield LF, Friedlander SF. Pediatric onychomycosis: the emerging role of topical therapy. J Drugs Dermatol. 2017;16(2):105–109.
- Totri CR, Feldstein S, Admani S, Friedlander SF, et al. Epidemiologic analysis of onychomycosis in the San Diego pediatric population. Pediatr Dermatol. 2017;34(1):46–49.
- Young LS, Arbuckle HA, Morelli JG. Onychomycosis in the Denver pediatrics population, a retrospective study. Pediatr Dermatol. 2014;31(1):106–108.
- Leibovici V, Evron R, Dunchin M, et al. A population-based study of toenail onychomycosis in Israeli children. Pediatr Dermatol. 2009;26(1):95–97.
- Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014;171(5):937–958.
- Gupta AK, Skinner AR. Onychomycosis in children: a brief overview with treatment strategies. Pediatr Dermatol. 2004;21(1):74–79.
- Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st century: an update on diagnosis, epidemiology, and treatment. J Cutan Med Surg. 2017;21(6):525–539.
- Lipner SR, Scher RK. Onychomycosis: clinical overview and diagnosis. J Am Acad Dermatol. 2019;80(4):835–851.
- Elewski BE. Onychomycosis: pathogenesis diagnosis and management. Clin Microbiol Rev. 1998;11(3):415–429.
- Haghani I, Shokohi T, Hajheidari Z, et al. Comparison of diagnostic methods in the evaluation of onychomycosis. Mycopathologia. 2013;175(3–4):315–321.
- Reisberger EM, Abels C, Landthaler M, et al. Histopathologic diagnosis of onychomycosis by periodic acid- Schiff-stained nail clippings. Br J Dermatol. 2003;148(4):749–754.
- Ginter-Hanselmayer G, Weger W, Smolle J. Onychomycosis: a new emerging infectious disease in childhood population and adolescents. Report on treatment experience with terbinafine and itraconazole in 36 patients. J Eur Acad Dermatol Venereol. 2008;22(4):470–475.
- Heikkilä H, Stubb S. Onychomycosis in children: treatment results of forty-seven patients. Acta Derm Venereol. 2002;82(6):484–485.
- Ginter G. Mycoses in children—systemic treatment. Acta Dermatovenerol Alp Panon Adriat. 1998;98(7):101–105.
- Gupta AK, Cooper EA, Montero-Gei F. The use of fluconazole to treat superficial fungal infections in children. Dermatol Clin. 2003;21(3):537–542.
- Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother. 1999;43(8):1955–1960.
- Eichenfield LF, Elewski B, Sugarman JL, et al. Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients: Open-Label Phase 4 Study [published online ahead of print, 2020 Jul 1]. J Am Acad Dermatol. 2020; S0190–9622(20)32104–6. [Online ahead of print]
- Eichenfield LF, Elewski B, Sugarman J, et al. Safety, pharmacokinetics, and efficacy of efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients. 2020 Maui Derm for Dermatologists Annual Meeting; 2020; Grand Wailea, Hawaii, USA.
- Jublia (Efinaconazole) Package Insert [Internet]. Bridgewater, NJ, USA; Drugs@FDA; 2014. [Revised 2020]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf.
- Rich P, Spellman M, Purohit V, et al. Tavaborole 5% topical solution for the treatment of toenail onychomycosis in pediatric patients: results from a phase 4 open-label study. J Drugs Dermatol. 2019;18(2):190–195.
- Kerydin (Tavaborole) Package Insert [Internet]. Drugs@FDA; 2018. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204427s006lbl.pdf.
- Friedlander SF, Chan YC, Chan YH, et al. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy. Pediatr Dermatol. 2013;30(3):316–322.
- Penlac (Ciclopirox) Package Insert [Internet]. Drugs@FDA; 2004. Available from: https://www.accessdata.fda.gov/drugsatfda.docs/label/2004/21022s004lbl.pdf.
- Center for Devices and Radiological Health. Medical devices and clinical trial design for the treatment or improvement in the appearance of fungally-infected nails. Guidance for Industry and Food and Drug Administration staff. [Internet] Issued on March 7, 2016. Available from: https://www.fda.gov/media/90831/download.
- Gupta AK, Foley KA, Versteeg SG. Lasers for onychomycosis: current status. J Cutan Med Surg. 2017;21(2):114–116.
- Gupta AK, Versteeg SG, Shear NH. Common drug-drug interactions in antifungal treatments for superficial fungal infections. Expert Opin Drug Metab Toxicol. 2018;14(4):387–398.
- Gupta AK, Cooper EA, Lynde CW. The efficacy and safety of terbinafine in children. Dermatol Clin. 2003;21(3):511–520.
- Gupta AK, Cooper EA, Ginter G. Efficacy and safety of itraconazole use in children. Dermatol Clin. 2003;21(3):521–535.
- Novartis. LAMISIL (terbinafine hydrochloride) oral granules, 125 mg or 187.5 mg. [Internet] Drugs@FDA; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022071s015lbl.pdf.
- Gupta AK, Venkataraman M, Shear NH, et al. Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis [published online ahead of print, 2020 May 17]. Dermatol Ther. 2020;:e13613.DOI:10.1111/dth.13613
- Novartis. LAMISIL (terbinafine hydrochloride) Tablets, 250 mg. [Internet] Drugs@FDA; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf.
- Janssen Pharma. SPORANOX® (itraconazole) Capsules. [Internet] Drugs@FDA; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020083s062lbl.pdf.
- Pfizer. Product monograph Diflucan [Internet] Drugs@FDA; (Revised); 2018. Available from: https://www.pfizer.ca/sites/default/files/201806/Diflucan_PM_E_207077_12June2018.pdf.
- Mayser P, Nenoff P, Reinel D, et al. S1 guidelines: Tinea capitis. J Dtsch Dermatol Ges. 2020;18(2):161–179.
- Ryder NS. The mechanism of action of terbinafine. Clin Exp Dermatol. 1989;14(2):98–100.
- Gupta AK, Adamiak A, Cooper EA. The efficacy and safety of terbinafine in children. J Eur Acad Dermatol Venereol. 2003;17(6):627–640.
- New antimicrobial agents approved by the U.S. Food and Drug Administration from 2007 to 2009 and new indications for previously approved agents. Antimicrob Agents Chemother. 2010;54(9):4033–4035.
- Gupta AK, Mays RR, Versteeg SG, et al. Tinea capitis in children: a systematic review of management. J Eur Acad Dermatol Venereol. 2018;32(12):2264–2274.
- Pfizer. DIFLUCAN (Fluconazole) Tablets 50 mg, 100 mg, 150 mg and 200 mg. Oral suspensions 350 mg or 1400 mg [Internet]. Drugs@FDA; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019949s065,020090s047lbl.pdf.
- Bueno J G, Martinez C, Zapata B, et al. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Clinical and Experimental Dermatology. 2009;35(6):658–663. doi:10.1111/j.1365-2230.2009.03698.x.
- Janssen Pharma. SPORANOX® (itraconazole) Oral solution [Internet]. Drugs@FDA; 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020657s027lbl.pdf.
- Brown SJ. Efficacy of fluconazole for the treatment of onychomycosis. Ann Pharmacother. 2009;43(10):1684–1691.
- Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol. 2000;43(4):S57–S69.
- Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43(4 Suppl):S70–S80.
- Valeant Canada LP. Product monograph Penlac [Internet]; 2012. Available from: https://pdf.hres.ca/dpd_pm/00015736.PDF.
- Gupta AK. Ciclopirox: an overview. Int J Dermatol. 2001;40(5):305–310.
- Jue SG, Dawson GW, Brogden RN. Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. Drugs. 1985;29(4):330–341.
- Loprox (ciclopirox) Nail Lacquer 8% Clinical pharmacology and biopharmaceutical FDA document [Internet]. Drugs@FDA; 2003. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21159_Loprox_biopharmr.pdf.
- Ceschin-Roques CG, Hänel H, Pruja-Bougaret SM, et al. Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin. Skin Pharmacol. 1991;4(2):89–94.
- Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J Am Podiatr Med Assoc. 2000;90(10):495–501.
- Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol. 2009;23(7):773–781.
- Piraccini BM, Tosti A. Ciclopirox hydroxypropyl chitosan: efficacy in mild-to-moderate onychomycosis . Skin Appendage Disord. 2018;5(1):13–19.
- Gupta AK, Stec N, Summerbell RC, et al. Onychomycosis: a review [published online ahead of print, 2020 Apr 1]. J Eur Acad Dermatol Venereol. 2020. DOI:10.1111/jdv.16394
- Gupta AK, Stec N. Recent advances in therapies for onychomycosis and its management. F1000Res. 2019;8:968.
- Piraccini BM, Iorizzo M, Lencastre A, et al. Ciclopirox hydroxypropyl chitosan (HPCH) nail lacquer: a review of its use in onychomycosis . Dermatol Ther. 2020. DOI:10.1007/s13555-020-00420-9. [Online ahead of print].
- Haria M, Bryson HM. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs. 1995;49(1):103–120.
- Polak A. Preclinical data and mode of action of amorolfine. Dermatology. 1992;184 (Suppl 1):3–7.
- Flagothier C, Piérard-Franchimont C, Piérard GE. New insights into the effect of amorolfine nail lacquer. Mycoses. 2005;48(2):91–94.
- Tabara K, Szewczyk AE, Bienias W, et al. Amorolfine vs. ciclopirox – lacquers for the treatment of onychomycosis. Postepy Dermatol Alergol. 2015;32(1):40–45.
- Marty JP. Amorolfine nail lacquer: a novel formulation. J Eur Acad Dermatol. 1995;5:17–21.
- Lauharanta JL. Comparative efficacy and safety of amorolfine anil lacquer 2% versus 5% once weekly. Clin Exp Dermatol. 1992;17(s1):41–43.
- Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol. 1992;17(s1):44–49.
- Accord. Amorolfine 5% w/v medicated nail lacquer package leaflet: information for the user [Internet]. emc; 2019 [cited 2020 May 28]: https://www.medicines.org.uk/emc/files/pil.3292.pdf.
- Accord. Amorolfine 5% w/v medicated nail lacquer summary of product characteristics [Internet]. emc; 2019. Available from: https://www.medicines.org.uk/emc/product/3292/smpc.
- Markinson B, Ghannoum M, Winter T, et al. Examining the benefits of the boron-based mechanism of action and physicochemical properties of tavaborole in the treatment of onychomycosis. J Am Podiatr Med Assoc. 2018;108(1):12–19.
- Gupta AK, Daigle D, Abramovits W. Tavaborole 5% solution for onychomycosis. Skinmed. 2015;13(1):55–58.
- Jinna S, Finch J. Spotlight on tavaborole for the treatment of onychomycosis. Drug Des Dev Ther. 2015;9:6185–6190.
- Zane LT, Plattner J, Chanda S, et al. Tavaborole topical solution, 5% for the development of toenail onychomycosis. Drugs of Today. 2015;51(10):599–607.
- Gupta AK, Versteeg SG. Tavaborole – a treatment for onychomycosis of the toenails. Expert Rev Clin Pharmacol. 2016;9(9):1145–1152.
- Gupta AK, Daigle D. Potential role of tavaborole for the treatment of onychomycosis. Future Microbiol. 2014;9(11):1243–1250.
- Murdan S. Drug delivery to the nail following topical application [published correction appears in. Int J Pharm. 2002;236(1–2):1–26.
- Hold KM, Bu W, Sanders V, et al. In vivo nail residence time of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis; 2007. www.anacor.com/pdf/poster_1816.pdf.
- Vlahovic T, MPharm TM, Chanda S, et al. Vitro nail penetration of tavaborole topical solution, 5%, through nail polish on ex vivo human fingernails. J Drugs Dermatol. 2015;14(7):675–678.
- Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73(1):62–69.
- Anacor Pharmaceuticals Inc. Tavaborole 5% solution medical review(s). [Internet] Drugs@FDA; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf.
- Elewski BE, Tosti A. tavaborole for the treatment of onychomycosis. Expert Opinion. 2014;15(10):1439–1448.
- Anacor Pharmaceuticals Inc. Tavaborole 5% solution pharmacology review(s).[Internet] Drugs@FDA; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000PharmR.pdf.
- Elewski BE, Vlahovic TC, Korotzer A. Topical treatment for onychomycosis: is it more effective than the clinical data suggests? J Clin Aesthet Dermatol. 2016;9(11):34–39.
- Gupta AK, Elewski BE, Sugarman JL, et al. The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials. J Drugs Dermatol. 2014;13(7):815–820.
- Jo Siu WJ, Tatsumi Y, Senda H, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013;57(4):1610–1616.
- Gupta AK, Simpson FC. Efinaconazole (Jublia) for the treatment of onychomycosis. Expert Rev Anti Infect Ther. 2014;12(7):743–752.
- Jo W, Glynn M, Nejishima H, et al. Nonclinical safety assessment of Efinaconazole solution (10%) for onychomycosis treatment. Regul Toxicol Pharmacol. 2014;70(1):242–253.
- Valeant Canada LP. Product monograph Jublia [Internet] 2017. Available from: https://pdf.hres.ca/dpd_pm/00040037.PDF.
- Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600–608.
- Tatsumi Y, Yokoo M, Senda H, et al. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Antimicrob Agents Chemother. 2002;46(12):3797–3801.
- Sugiura K, Sugimoto N, Hosaka S, et al. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment. Antimicrob Agents Chemother. 2014;58(7):3837–3842.
- Sakamoto M, Sugimoto N, Kawabata H, et al. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails. J Drugs Dermatol. 2014;13(11):1388–1392.
- Gupta AK, Studholme C. Update on efinaconazole 10% topical solution for the treatment of onychomycosis. Skin Therapy Lett. 2016;21(6):7–11.
- Elewski BE, Pollak RA, Pillai R, et al. Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space. J Drugs Dermatol. 2014;13(11):1394–1398.
- Zeichner JA, Stein Gold L, Korotzer A. Penetration of ((14)C)-efinaconazole topical solution 10%, does not appear to be influenced by nail polish [Published Correction Appears]. J Clin Aesthet Dermatol. 2014;7(9):34–36.
- Gupta AK, Cernea M. How effective is efinaconazole in the management of onychomycosis? Expert Opin Pharmacother. 2016;17(4):611–618.
- Jarratt M, Siu WJ, Yamakawa E, et al. Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis. J Drugs Dermatol. 2013;12(9):1010–1016.
- Valeant Canada. Efinaconazole 10% solution medical review(s). [Internet] Drugs@FDA; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203567Orig1s000MedR.pdf.
- Valeant Canada. Efinaconazole 10% solution pharmacology(s). [Internet] Drugs@FDA; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203567Orig1s000PharmR.pdf.
- Tosti A. Efinaconazole solution 10%: topical antifungal therapy for toenail onychomycosis. Cutis. 2013;92(4):203–208.
- Tosti A, Piraccini BM, Stinchi C, et al. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology. 1998;197(2):162–166.
- Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138(3):353–357.
- Gupta AK, Cooper EA, Paquet M. Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono- and combined therapy of terbinafine and itraconazole. J Cutan Med Surg. 2013;17(3):201–206.
- Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol. 1997;37(5 Pt 1):740–745.
- Gupta AK, Elewski BE, Rosen T, et al. Onychomycosis: strategies to minimize recurrence. J Drugs Dermatol. 2016;15(3):279–282.
- Shemer A, Gupta AK, Kamshov A, et al. Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure. Dermatol Ther. 2017;30(5). DOI:10.1111/dth.12545
- Gupta AK, Baran R, Summerbell R. Onychomycosis: strategies to improve efficacy and reduce recurrence. J Eur Acad Dermatol Venereol. 2002;16(6):579–586.
- Gupta AK, De Rosso JQ. Management of onychomycosis in children. Postgrad Med. 1999;:31–37.
- Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf. 2000;22(1):33–52.
- Piraccini BM, Starace M, Bruni F. Onychomycosis in children. Expert Rev Dermatol. 2012;7(6):569–578.
- Faergemann J, Correia O, Nowicki R, et al. Genetic predisposition-understanding underlying mechanisms of onychomycosis. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):17–19.
- Chang P, Logemann H. Onychomycosis in children. Int J Dermatol. 1994;33(8):550–551.
- Gupta AK, Brintnell WC. Sanitization of contaminated footwear from onychomycosis patients using ozone gas: a novel adjunct therapy for treating onychomycosis and tinea pedis? J Cutan Med Surg. 2013;17(4):243–249.
- Ghannoum MA, Isham N, Long L. Optimization of an infected shoe model for the evaluation of an ultraviolet shoe sanitizer device. J Am Podiatr Med Assoc. 2012;102(4):309–313.
- Hammer TR, Mucha H, Hoefer D. Infection risk by dermatophytes during storage and after domestic laundry and their temperature-dependent inactivation. Mycopathologia. 2011;171(1):43–49.
- Hull PR. Onychomycosis-treatment, relapse and re-infection. Dermatology. 1997;194(Suppl 1):7–9.
- Markinson B, Caldwell B. Efinaconazole topical solution, 10% efficacy in patients with onychomycosis and coexisting Tinea pedis. J Am Podiatr Med Assoc. 2015;105(5):407–411.
- Gupta AK, Paquet M. Systemic antifungals to treat onychomycosis in children: a systematic review. Pediatr Dermatol. 2013;30(3):294–302.